### <u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

# Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier		No
name, catalogue number and RRID, if available.		antibod
		ies
Cell materials	Yes (indicate where provided: section/paragraph)	n/a
<b>Cell lines:</b> Provide species information, strain.	res (malcale where provided, section/paragraph)	Not Cell
Provide accession number in repository <b>OR</b>		lines
supplier name, catalog number, clone number,		intes
OR RRID		
Primary cultures: Provide species, strain, sex of		Not
origin, genetic modification status.		Primary
		cultures
Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age,	, r, r, r	Not
genetic modification status. Provide accession		Experim
number in repository <b>OR</b> supplier name, catalog		ental
number, clone number, <b>OR</b> RRID		animals
Animal observed in or captured from the		Not
field: Provide species, sex and age where		Experim
possible		ental
		animals
Model organisms: Provide Accession number		Not
in repository (where relevant) <b>OR</b> RRID		Experim
		ental
		animals
Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession		Not
number if available, and source (including location		Plants
for collected wild specimens)		
Microbes: provide species and strain, unique		Not
accession number if available, and source		Microb
		es
Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or	Yes (indicate where provided: section/paragraph) The study was approved by the Institutional Review	n/a
	The study was approved by the Institutional Review Board of Children's Hospital of Chongqing Medical	n/a
Identify authority granting ethics approval (IRB or	The study was approved by the Institutional Review Board of Children's Hospital of Chongqing Medical University (file no. 2018-02) (the Methods section,	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number	The study was approved by the Institutional Review Board of Children's Hospital of Chongqing Medical	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number	The study was approved by the Institutional Review Board of Children's Hospital of Chongqing Medical University (file no. 2018-02) (the Methods section,	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	The study was approved by the Institutional Review Board of Children's Hospital of Chongqing Medical University (file no. 2018-02) (the Methods section, the first paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. Provide statement confirming informed consent	The study was approved by the Institutional Review Board of Children's Hospital of Chongqing Medical University (file no. 2018-02) (the Methods section, the first paragraph) each participant's statutory guardian signed the	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. Provide statement confirming informed consent	The study was approved by the Institutional Review Board of Children's Hospital of Chongqing Medical University (file no. 2018-02) (the Methods section, the first paragraph) each participant's statutory guardian signed the informed consent (the Methods section, the first	n/a

#### <u>Design</u>

Study protocol	Yes (indicate where provided:	n/a
For clinical trials, provide the trial registration number <b>OR</b> cite DOI in manuscript.		Not clinical trials
Laboratory protocol Provide DOI or other citation details if detailed step-	Yes (indicate where provided:	n/a Not
by-step protocols are available.		Laboratory protocol
<b>Experimental study design (statistics details)</b> State whether and how the following have been done, <b>or</b> if they were not carried out.	Yes (indicate where provided:	n/a
Sample size determination		No Sample size determinatio n
Randomisation		No Randomisatio n
Blinding		No Blinding
Inclusion/exclusion criteria	V (the Methods section, the second	
Sample definition and in-laboratory replication	Yes (indicate where provided:	n/a
State number of times the experiment was		Not Sample
replicated in laboratory		definition and
		in-laboratory
Define whether date describe technical enhibition		replication
Define whether data describe technical or biological replicates		Not Sample definition and
replicates		in-laboratory
		replication
Ethics	Yes (indicate where provided:	n/a
Studies involving human participants: State details of	The study was approved by the Institutional	
authority granting ethics approval (IRB or equivalent	Review Board of Children's Hospital of	
committee(s), provide reference number for	Chongqing Medical University (file no. 2018-	
approval.	02) (the Methods section, the first paragraph)	
Studies involving experimental animals: State details		No
of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		experimental animals
Studies involving specimen and field samples: State if		No specimen
relevant permits obtained, provide details of		and field
authority approving study; if none were required, explain why.		samples
Dual Use Research of Concern (DURC)	Yes (indicate where provided:	n/a
If study is subject to dual use research of concern,		Not Dual Use
state the authority granting approval and reference number for the regulatory approval		Research of
number for the regulatory approval		Concern

# <u>Analysis</u>

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	the Methods section, the second paragraph	
Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	All the data were analyzed by Graphpad Prism 7. Descriptive parameters, including means and standard deviations for normally distributed continuous data, frequencies, and percentages for categorical data, were calculated. Pearson's x2 test or Fisher's exact test was used to determine the association between categorical variables. The Mann–Whitney U test was used to compare numerical data between groups, while Spearman's rank test was used to assess correlations. (the Methods section, the fourth paragraph)	
Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.		No newly created datasets
If data are publicly available, provide accession number in repository or DOI or URL.		No publicly

number in repository or DOI or URL.	publicly available
	data
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	No publicly available data

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential		
for replicating the main findings of the study:		
State whether the code or software is available.		No code and software
If code is publicly available, provide accession number in repository, or DOI or URL.		No code

### **Reporting**

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal follows	
ARRIVE) have been followed, and whether a checklist	ICMJE recommendations for publication.	
(eg., CONSORT, PRISMA, ARRIVE) is provided with		
the manuscript.		

Article Information: http://dx.doi.org/10.21037/atm-20-7314